instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthritis gonococcal'. | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | PREDNISONE | DrugsGivenReaction | CC BY-NC | 33928799 | 19,836,071 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | PREDNISONE | DrugsGivenReaction | CC BY-NC | 33928799 | 19,836,071 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gonococcal infection'. | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | COLCHICINE, PREDNISONE | DrugsGivenReaction | CC BY-NC | 33928799 | 19,901,086 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | PREDNISONE | DrugsGivenReaction | CC BY-NC | 33928799 | 19,836,071 | 2021 |
What was the outcome of reaction 'Arthritis gonococcal'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovered | ReactionOutcome | CC BY-NC | 33928799 | 19,836,071 | 2021 |
What was the outcome of reaction 'Condition aggravated'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovered | ReactionOutcome | CC BY-NC | 33928799 | 19,836,071 | 2021 |
What was the outcome of reaction 'Encephalopathy'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovering | ReactionOutcome | CC BY-NC | 33928799 | 19,901,086 | 2021 |
What was the outcome of reaction 'Gonococcal infection'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovering | ReactionOutcome | CC BY-NC | 33928799 | 19,901,086 | 2021 |
What was the outcome of reaction 'Hydrocephalus'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovering | ReactionOutcome | CC BY-NC | 33928799 | 19,901,086 | 2021 |
What was the outcome of reaction 'Hyponatraemia'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovered | ReactionOutcome | CC BY-NC | 33928799 | 19,901,086 | 2021 |
What was the outcome of reaction 'Meningitis gonococcal'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovering | ReactionOutcome | CC BY-NC | 33928799 | 19,901,086 | 2021 |
What was the outcome of reaction 'Rash'? | Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis.
Neisseria gonorrhoeae, a gram-negative coccus, is a major cause of morbidity among sexually active individuals. Hematogenous spread of N gonorrhoeae from the initial site of infection is thought to occur in only 0.5% to 3% of infected patients.... | Recovered | ReactionOutcome | CC BY-NC | 33928799 | 19,836,071 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleural effusion'. | Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33931705 | 20,197,835 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tumour pseudoprogression'. | Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33931705 | 20,197,835 | 2021-04-30 |
What was the dosage of drug 'PEMBROLIZUMAB'? | Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17... | 8 CYCLES | DrugDosageText | CC BY | 33931705 | 20,197,835 | 2021-04-30 |
What was the outcome of reaction 'Tumour pseudoprogression'? | Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17... | Recovered | ReactionOutcome | CC BY | 33931705 | 20,197,835 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | CISPLATIN, NELFINAVIR MESYLATE | DrugsGivenReaction | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | CISPLATIN, NELFINAVIR MESYLATE | DrugsGivenReaction | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypokalaemia'. | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | CISPLATIN, NELFINAVIR MESYLATE | DrugsGivenReaction | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypomagnesaemia'. | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | CISPLATIN, NELFINAVIR MESYLATE | DrugsGivenReaction | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | CISPLATIN, NELFINAVIR MESYLATE | DrugsGivenReaction | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
What was the administration route of drug 'NELFINAVIR MESYLATE'? | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
What was the dosage of drug 'CISPLATIN'? | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | 40 MG/M2, WEEKLY (FOR 6 CYCLES) | DrugDosageText | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
What was the dosage of drug 'NELFINAVIR MESYLATE'? | Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
BACKGROUND
Nelfinavir (NFV), an HIV-1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate sa... | 875 MG, 2X/DAY (DL1, 7 DAYS BEFORE THE INITIATION OF CRT) | DrugDosageText | CC BY-NC-ND | 33932031 | 19,271,025 | 2021-07-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Dabrafenib is an oral BRAF kinase inhibitor approved for the treatment of various BRAF V600 mutation-positive solid tumors. In vitro observations suggesting c... | ROSUVASTATIN | DrugsGivenReaction | CC BY-NC-ND | 33932130 | 20,824,392 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute graft versus host disease in intestine'. | Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.
BACKGROUND
Parvovirus B19 (PVB19) infection has been implicated in allograft failure or dysfunction in solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the literatur... | ALEMTUZUMAB, FLUDARABINE PHOSPHATE, MELPHALAN, THIOTEPA | DrugsGivenReaction | CC BY | 33932151 | 17,412,425 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancytopenia'. | Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.
BACKGROUND
Parvovirus B19 (PVB19) infection has been implicated in allograft failure or dysfunction in solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the literatur... | CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS | DrugsGivenReaction | CC BY | 33932151 | 17,396,520 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Transplant failure'. | Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.
BACKGROUND
Parvovirus B19 (PVB19) infection has been implicated in allograft failure or dysfunction in solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the literatur... | CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS | DrugsGivenReaction | CC BY | 33932151 | 17,396,520 | 2021-05-01 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.
BACKGROUND
Parvovirus B19 (PVB19) infection has been implicated in allograft failure or dysfunction in solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the literatur... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33932151 | 17,396,520 | 2021-05-01 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.
BACKGROUND
Parvovirus B19 (PVB19) infection has been implicated in allograft failure or dysfunction in solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the literatur... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33932151 | 17,396,520 | 2021-05-01 |
What was the dosage of drug 'TACROLIMUS'? | Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.
BACKGROUND
Parvovirus B19 (PVB19) infection has been implicated in allograft failure or dysfunction in solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the literatur... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33932151 | 17,396,520 | 2021-05-01 |
What was the outcome of reaction 'Pancytopenia'? | Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.
BACKGROUND
Parvovirus B19 (PVB19) infection has been implicated in allograft failure or dysfunction in solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the literatur... | Not recovered | ReactionOutcome | CC BY | 33932151 | 17,396,520 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bladder neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Breast neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bronchial neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colon neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastric neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haematological malignancy'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatobiliary neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hodgkin^s disease'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Kaposi^s sarcoma'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukaemia monocytic'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukaemia'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphocytic leukaemia'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant melanoma'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myeloid leukaemia'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm prostate'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm skin'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oesophageal neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ovarian neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancreatic neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pharyngeal neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Plasma cell myeloma'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rectal neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thyroid neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Uterine neoplasm'. | The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
BACKGROUND
Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) i... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 33932917 | 19,575,831 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma
The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic asthma (SEA). However, reports on experience with me... | BECLOMETHASONE DIPROPIONATE, MEPOLIZUMAB, METHYLPREDNISOLONE, MONTELUKAST SODIUM | DrugsGivenReaction | CC BY | 33932968 | 19,267,059 | 2021-08-30 |
What was the administration route of drug 'BECLOMETHASONE DIPROPIONATE'? | Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma
The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic asthma (SEA). However, reports on experience with me... | Respiratory (inhalation) | DrugAdministrationRoute | CC BY | 33932968 | 19,267,059 | 2021-08-30 |
What was the administration route of drug 'MEPOLIZUMAB'? | Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma
The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic asthma (SEA). However, reports on experience with me... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33932968 | 19,267,059 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mental status changes'. | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | ENZALUTAMIDE, LEUPROLIDE, PREDNISONE | DrugsGivenReaction | CC BY | 33933029 | 19,508,573 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia aspiration'. | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | ENZALUTAMIDE, LEUPROLIDE, PREDNISONE | DrugsGivenReaction | CC BY | 33933029 | 19,508,573 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | ENZALUTAMIDE, LEUPROLIDE ACETATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933029 | 19,478,701 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | ENZALUTAMIDE, LEUPROLIDE, PREDNISONE | DrugsGivenReaction | CC BY | 33933029 | 19,508,573 | 2021-05-01 |
What was the administration route of drug 'LEUPROLIDE ACETATE'? | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | Intramuscular | DrugAdministrationRoute | CC BY | 33933029 | 19,478,701 | 2021-05-01 |
What was the administration route of drug 'PREDNISONE'? | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | Oral | DrugAdministrationRoute | CC BY | 33933029 | 19,478,701 | 2021-05-01 |
What was the outcome of reaction 'Bacterial infection'? | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | Recovered | ReactionOutcome | CC BY | 33933029 | 19,478,701 | 2021-05-01 |
What was the outcome of reaction 'Mental status changes'? | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | Recovered | ReactionOutcome | CC BY | 33933029 | 19,508,573 | 2021-05-01 |
What was the outcome of reaction 'Pneumonia aspiration'? | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | Recovered | ReactionOutcome | CC BY | 33933029 | 19,508,573 | 2021-05-01 |
What was the outcome of reaction 'Pneumonia'? | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | Recovered | ReactionOutcome | CC BY | 33933029 | 19,478,701 | 2021-05-01 |
What was the outcome of reaction 'Sepsis'? | Carnobacterium inhibens isolated in blood culture of an immunocompromised, metastatic cancer patient: a case report and literature review.
BACKGROUND
Carnobacterium species are lactic acid-producing Gram-positive bacteria that have been approved by the US Food and Drug Administration and Health Canada for use as a food... | Recovered | ReactionOutcome | CC BY | 33933029 | 19,508,573 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | AZACITIDINE, BUSULFAN, CYTARABINE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, VENETOCLAX | DrugsGivenReaction | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Klebsiella infection'. | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | AZACITIDINE, BUSULFAN, CYTARABINE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, VENETOCLAX | DrugsGivenReaction | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | AZACITIDINE, BUSULFAN, CYTARABINE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, VENETOCLAX | DrugsGivenReaction | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Systemic mycosis'. | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | AZACITIDINE, BUSULFAN, CYTARABINE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, VENETOCLAX | DrugsGivenReaction | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
What was the dosage of drug 'DAUNORUBICIN'? | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | 60 MG/M2 DAILY; INDUCTION CHEMOTHERAPY | DrugDosageText | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
What was the outcome of reaction 'Febrile neutropenia'? | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | Recovered | ReactionOutcome | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
What was the outcome of reaction 'Klebsiella infection'? | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | Recovered | ReactionOutcome | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
What was the outcome of reaction 'Sepsis'? | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | Recovered | ReactionOutcome | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
What was the outcome of reaction 'Systemic mycosis'? | The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available li... | Recovered | ReactionOutcome | CC BY | 33933047 | 19,651,919 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthritis'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,266,362 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Coccidioidomycosis'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE SODIUM, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,300,097 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,266,362 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | ABATACEPT, INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,371,701 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fibromyalgia'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,266,362 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Juvenile idiopathic arthritis'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,308,431 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,266,362 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Phonophobia'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,308,431 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,308,431 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Retinal pigment epitheliopathy'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,280,132 | 2021-05-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy interrupted'. | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | INFLIXIMAB, METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 33933122 | 19,266,362 | 2021-05-01 |
What was the administration route of drug 'ABATACEPT'? | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | Other | DrugAdministrationRoute | CC BY | 33933122 | 19,371,701 | 2021-05-01 |
What was the dosage of drug 'ABATACEPT'? | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | 10MG/KG ONCE IN 4 WEEKS | DrugDosageText | CC BY | 33933122 | 19,371,701 | 2021-05-01 |
What was the dosage of drug 'METHOTREXATE SODIUM'? | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | 10 MG, WEEKLY | DrugDosageText | CC BY | 33933122 | 19,300,097 | 2021-05-01 |
What was the dosage of drug 'PREDNISOLONE'? | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | 10 MILLIGRAM PER DAY | DrugDosageText | CC BY | 33933122 | 19,312,275 | 2021-05-01 |
What was the outcome of reaction 'Chorioretinitis'? | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | Recovered | ReactionOutcome | CC BY | 33933122 | 19,266,362 | 2021-05-01 |
What was the outcome of reaction 'Coccidioidomycosis'? | Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
BACKGROUND
Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with... | Recovered | ReactionOutcome | CC BY | 33933122 | 19,300,097 | 2021-05-01 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.